Highly	O
specific	O
epigenome	O
editing	O
by	O
CRISPR	O
-	O
Cas9	O
repressors	O
for	O
silencing	O
of	O
distal	O
regulatory	O
elements	O
.	O


Epigenome	O
editing	O
with	O
the	O
CRISPR	O
(	O
clustered	O
,	O
regularly	O
interspaced	O
,	O
short	O
palindromic	O
repeats	O
)	O
-	O
Cas9	O
platform	O
is	O
a	O
promising	O
technology	O
for	O
modulating	O
gene	O
expression	O
to	O
direct	O
cell	O
phenotype	O
and	O
to	O
dissect	O
the	O
causal	O
epigenetic	O
mechanisms	O
of	O
gene	O
regulation	O
.	O


Fusions	O
of	O
nuclease	O
-	O
inactive	O
dCas9	O
to	O
the	O
Kruppel	O
-	O
associated	O
box	O
(	O
KRAB	O
)	O
repressor	O
(	O
dCas9	O
-	O
KRAB	O
)	O
can	O
silence	O
target	O
gene	O
expression	O
,	O
but	O
the	O
genome	O
-	O
wide	O
specificity	O
and	O
the	O
extent	O
of	O
heterochromatin	O
formation	O
catalyzed	O
by	O
dCas9	O
-	O
KRAB	O
are	O
not	O
known	O
.	O


We	O
targeted	O
dCas9	O
-	O
KRAB	O
to	O
the	O
HS2	O
enhancer	O
,	O
a	O
distal	O
regulatory	O
element	O
that	O
orchestrates	O
the	O
expression	O
of	O
multiple	O
globin	O
genes	O
,	O
and	O
observed	O
highly	O
specific	O
induction	O
of	O
H3K9	O
trimethylation	O
(	O
H3K9me3	O
)	O
at	O
the	O
enhancer	O
and	O
decreased	O
chromatin	O
accessibility	O
of	O
both	O
the	O
enhancer	O
and	O
its	O
promoter	O
targets	O
.	O


Targeted	O
epigenetic	O
modification	O
of	O
HS2	O
silenced	O
the	O
expression	O
of	O
multiple	O
globin	O
genes	O
,	O
with	O
minimal	O
off	O
-	O
target	O
changes	O
in	O
global	O
gene	O
expression	O
.	O


These	O
results	O
demonstrate	O
that	O
repression	O
mediated	O
by	O
dCas9	O
-	O
KRAB	O
is	O
sufficiently	O
specific	O
to	O
disrupt	O
the	O
activity	O
of	O
individual	O
enhancers	O
via	O
local	O
modification	O
of	O
the	O
epigenome	O
.	O
